Robert Cavorsi - 19 Apr 2024 Form 3 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
Vice President, Strategy
Signature
/s/ William R. Kolb, Attorney-in-Fact
Issuer symbol
ORGO
Transactions as of
19 Apr 2024
Net transactions value
$0
Form type
3
Filing time
29 Apr 2024, 16:22:57 UTC
Next filing
18 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ORGO Class A Common Stock 23,579 19 Apr 2024 Direct F2
holding ORGO Class A Common Stock 739 19 Apr 2024 Direct F1, F3
holding ORGO Class A Common Stock 215 19 Apr 2024 Direct F1, F3
holding ORGO Class A Common Stock 2,163 19 Apr 2024 Direct F1, F4
holding ORGO Class A Common Stock 4,203 19 Apr 2024 Direct F1, F5
holding ORGO Class A Common Stock 51,750 19 Apr 2024 Direct F1, F6
holding ORGO Class A Common Stock 57,434 19 Apr 2024 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ORGO Stock Option (Right to Buy) 19 Apr 2024 Class A Common Stock 6,519 $15.63 Direct F8
holding ORGO Stock Option (Right to Buy) 19 Apr 2024 Class A Common Stock 32,559 $14.45 Direct F9
holding ORGO Stock Option (Right to Buy) 19 Apr 2024 Class A Common Stock 19,935 $8.03 Direct F10
holding ORGO Stock Option (Right to Buy) 19 Apr 2024 Class A Common Stock 81,000 $2.51 Direct F11
holding ORGO Stock Option (Right to Buy) 19 Apr 2024 Class A Common Stock 103,842 $3.43 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock.
F2 Represents shares of Class A Common Stock of Organogenesis pursuant to vested RSUs under the 2018 Equity Incentive Plan.
F3 The RSUs vest in equal annual installments over four years beginning March 9, 2021, and shall become fully vested on March 9, 2025.
F4 The RSUs vest in equal annual installments over four years beginning July 16, 2021, and shall become fully vested on July 16, 2025.
F5 The RSUs vest in equal annual installments over four years beginning March 1, 2022, and shall become fully vested on March 1, 2026.
F6 The RSUs vest in equal annual installments over four years beginning February 15, 2023, and shall become fully vested on February 15, 2027.
F7 The RSUs vest in equal annual installments over four years beginning February 15, 2024, and shall become fully vested on February 15, 2028.
F8 The option becomes exercisable in equal annual installments over four years beginning March 9, 2021, and shall become fully vested and exercisable on March 9, 2025.
F9 The option becomes exercisable in equal annual installments over four years beginning July 16, 2021, and shall become fully vested and exercisable on July 16, 2025.
F10 The option becomes exercisable in equal annual installments over four years beginning March 1, 2022, and shall become fully vested and exercisable on March 1, 2026.
F11 The option becomes exercisable in equal annual installments over four years beginning February 15, 2023, and shall become fully vested and exercisable on February 15, 2027.
F12 The option becomes exercisable in equal annual installments over four years beginning February 15, 2024, and shall become fully vested and exercisable on February 15, 2028.

Remarks:

Exhibit 24 Power of Attorney filed herewith.